Engineering future vaccines

Sferogen is a cutting-edge biotech company developing next-generation vaccines

lab
Current situation

Few innovations stand out as important as vaccines in the history of modern medicine.

The nanoSFERIC platform allows for a tailored approach, promising precise and safe immune response against target epitopes.

Sferogen is a cutting-edge biotech company that is developing next-generation vaccines.

Technology

We developed nanoSFERIC, a proprietary self-assembling protein nanoparticle platform with superior immunogenicity

The assembled nanoSFERIC particles form immunogenic rings with repeating target epitopes in eukaryotic and prokaryotic expression systems.

The planar presentation of repeating epitopes to B cells augments cross-linking of the immune receptors, boosting cell activation and specific antibody production.

Platform diversity

Infectious disease

Onc­ology

Veter­inary

Anti­bacterial

Immunomo­dulatory

Diagn­ostics

Pipeline
pipeline

We are addressing pandemic preparedness with nanoSFERIC Nipah virus vaccine candidate.

nanosferic structure
Nipah epidemics occur annually, and there is currently no vaccine or treatment available.
The development of an inactivated/attenuated Nipah virus vaccine would require a high-containment biosafety level facility.
The platform demonstrated rapid antibody response.
Accessible and transferable technology will enable a One-Health approach to target both animals and humans.
Nipah is a zoonotic virus with a high morbidity and mortality rate.
Services

Enveloped virus-like particles (eVLP)

The enveloped virus-like particles mimic the native virion, thereby eliciting a complete and natural multi-valent immune response. This technology offers a safe and well-known production system of vaccines against the most dangerous viral patogens.

R&D and manufacturing services

At Sferogen, we have developed a proprietary eVLP manufacturing pipeline to achieve clinical-grade vaccine purity, paving the way to the clinic.

The team

In our team, experts from diverse fields have joined forces to accelerate the journey from discovery to clinic.

Urban BEZELJAK

Urban BEZELJAK

PhD, CEO and
Chief R&D

At Sferogen, Urban is the leading inventor of the proprietary nanoSFERIC vaccine platform, leading the research and design of this versatile technology. Urban is a molecular biology and biochemistry expert with experience in mammalian and insect cell culture expression technology. He earned his Master's degree in biochemistry at the University of Ljubljana (Slovenia) and holds a PhD from the Institute of Science and Technology Austria.
Alexander JERMAN

Alexander JERMAN

MD, CMO,
nephrologist

At Sferogen, Alexander is working closely with the advisory committee to identify new targets, plan preclinical trials and pave the way for the first-in human trials. Alexander is a scientist-physician with experience in immunology, nephrology and blood-purification. He holds an M.D. with honors from the University of Ljubljana and is a certified nephrologist.
Uroš FERJANČIČ

Uroš FERJANČIČ

MSc, COO,
tech transfer specialist

As chief operating officer at Sferogen, Uroš is responsible for planning and implementing of the company's daily operational functions, including management of purchasing, accounting (ERP, IT, IP), intellectual property, infrastructure, marketing, business planning, and branding. With over two decades of experience in sales, marketing, and manufacturing processes, Uroš brings a specialized interest in technology transfer to the role.
Matjaž PETERKA

Matjaž PETERKA

PhD,
Business Development

Matjaž is co-founder of Sferogen, guiding the long-term research strategy and overseeing business development activities. With over 20 years of leadership experience in the biotech industry, Matjaž has a proven track record in multifaceted roles, including extensive expertise in the manufacturing of viral vaccines, and bioprocess control.
Our story

Sferogen was established in 2022 as a spin-off company from COBIK, a research and development organization in the field of biotechnology.

eVLP

We developed an enveloped virus-like particle (eVLP) lead COVID-19 vaccine candidate, nSfCoVac, using a high-throughput insect cell line. This vaccine consists of three main SARS-CoV-2 structural proteins. We introduced innovative purification steps to yield pure virus-like particles with the desired morphology. Preclinical studies on a mouse model proved the immunogenicity on par with approved vaccines.

nanoSFERIC

We developed an innovative recombinant nanoSFERIC platform that has a number of key features, including a modular design, fast antigen switching, and scalable production. Our lead vaccine candidate demonstrated a strong immune response after single dose in a preclinical model antibody response.

Contact

Work with us

Our aim is to turn most innovative ideas into reality. That is why we are constantly challenging concepts, seeking new ideas and looking for bold, pioneering partners.

We believe that next decade will wittnes paradigm shifts in our understanding of immune system and system biology. This, in concert with current pace of innovation in biotechnology will enable the design of novel, better and safer vaccines for global health. On the other side, our ability to recognize and tackle personalized traits in oncology will exponentially expand the area of personalized medicine. This will result in bringing together the multiple layers of current knowledge and expertise into a One Health.

We are looking for innovative talents in research, biotechnology, clinical medicine and regulation to help us achieve our abitious goals.

Writte or call us on:

+386(0)40 54 84 64
info@sferogen.com